Cargando…

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers

There is a vital need for improved therapeutic strategies that are effective in both primary and metastatic triple-negative breast cancer (TNBC). Current treatment options for TNBC patients are restricted to chemotherapy; however tyrosine kinases are promising druggable targets due to their high exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Linklater, Erik S., Tovar, Elizabeth A., Essenburg, Curt J., Turner, Lisa, Madaj, Zachary, Winn, Mary E., Melnik, Marianne K., Korkaya, Hasan, Maroun, Christiane R., Christensen, James G., Steensma, Matthew R., Boerner, Julie L., Graveel, Carrie R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342523/ https://www.ncbi.nlm.nih.gov/pubmed/27655711 http://dx.doi.org/10.18632/oncotarget.12065

Ejemplares similares

Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities
por: Grit, Jamie L., et al.
Publicado: (2020)

NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer
por: Dischinger, Patrick S., et al.
Publicado: (2018)

Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling
por: Grit, Jamie L., et al.
Publicado: (2021)

Germline Met Mutations in Mice Reveal Mutation- and Background-Associated Differences in Tumor Profiles
por: Graveel, Carrie R., et al.
Publicado: (2010)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
por: Lanning, Nathan J., et al.
Publicado: (2017)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines
por: Gusenbauer, Simone, et al.
Publicado: (2015)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

Critical analysis of the potential for microRNA biomarkers in breast cancer management
por: Graveel, Carrie R, et al.
Publicado: (2015)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
por: Mehta, Rajeshwari, et al.
Publicado: (2013)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
por: Simiczyjew, Aleksandra, et al.
Publicado: (2018)

Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells
por: Stern, Yaakov E., et al.
Publicado: (2022)

EGFR transactivates RON to drive oncogenic crosstalk
por: Franco Nitta, Carolina, et al.
Publicado: (2021)

Circles within circles: crosstalk between protein Ser/Thr/Tyr-phosphorylation and Met oxidation
por: Rao, R Shyama Prasad, et al.
Publicado: (2013)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
por: McKnight, Brooke N., et al.
Publicado: (2020)

Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy
por: Xie, Qian, et al.
Publicado: (2013)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D
por: Johnson, Christian W., et al.
Publicado: (2019)

Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy
por: Liu, Xin, et al.
Publicado: (2020)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer
por: Shin, Sung-Young, et al.
Publicado: (2018)

Involvement of lipid rafts in adhesion-induced activation of Met and EGFR
por: Lu, Ying-Che, et al.
Publicado: (2011)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

Crosstalk between triple negative breast cancer and microenvironment
por: Smrekar, Karly, et al.
Publicado: (2023)

Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer
por: Berasain, Carmen, et al.
Publicado: (2011)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
por: Baker, Andrew T., et al.
Publicado: (2014)

EGFR Signal-Network Reconstruction Demonstrates Metabolic Crosstalk in EMT
por: Choudhary, Kumari Sonal, et al.
Publicado: (2016)

Wnt/β-catenin Signaling in Normal and Cancer Stem Cells
por: Valkenburg, Kenneth C., et al.
Publicado: (2011)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Sialyl Lewis(X/A) and Cytokeratin Crosstalk in Triple Negative Breast Cancer
por: Pascoal, Carlota, et al.
Publicado: (2023)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mo53m7rh7nal0l6c2pdcnp8367